A bold new strategic roadmap, dubbed "Metabolic Frontier 2030," has been unveiled, targeting a major leap forward in obesity and metabolic health treatments. The plan aims to deliver five new product launches and advance over ten clinical programs by the end of the decade.

The strategy hinges on a multi-pronged approach to accelerate innovation:

• AI-Driven Discovery: Leveraging advanced artificial intelligence to streamline and enhance research and development.
• Strategic Partnerships: Forming new collaborations to broaden expertise and resources.
• Geographic Expansion: Establishing a new research site in Boston, a global hub for biotech innovation, to tap into leading scientific talent.

The first major clinical milestones from this pipeline are anticipated around 2026. This initiative represents a significant concentrated effort to address the growing global health challenges of obesity and related metabolic diseases through next-generation therapies.